PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
-0.10
Negative D/E while AXSM shows 2.95. Joel Greenblatt would look for hidden assets and restructuring catalysts.
0.91
Net debt less than half of AXSM's 2.39. Charlie Munger would approve but verify if excess conservatism is warranted given competitive dynamics.
No Data
No Data available this quarter, please select a different quarter.
0.79
Current ratio 50-75% of AXSM's 1.57. Bill Ackman would demand clear path to liquidity improvement.
No Data
No Data available this quarter, please select a different quarter.